This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy Study of the Use of Sequential DFP-DFO Versus DFP (SEQDFPDFO)

This study has been completed.
Information provided by:
Azienda Ospedaliera V. Cervello Identifier:
First received: August 11, 2008
Last updated: August 12, 2008
Last verified: July 2008

Changes in chelation treatment and transfusion practices, during the past two decades, have dramatically improved the prognosis of thalassemia major patients.Deferiprone (DFP) has been compared with deferoxamine (DFO), using different schedules of treatment, in the majority of the 13 clinical trials published between 1990 and 2008.No statistically significant difference was shown between these two interventions during, at most, 18 months of treatment.Three randomised trials that compared sequential DFP-DFO treatment versus DFO alone reported controversial results but this could be due to small sample sizes and short treatment duration. In fact, no trial with treatment duration longer than 18 months15, which reported on mortality, adverse events, serum ferritin concentrations, as well as costs has so far been published.

This long-term sequential DFP-DFO treatment versus DFP alone treatment trial was conducted to assess the impacts of these chelation treatments on serum ferritin concentrations, mortality, adverse events, and costs in thalassemia major patients.

Condition Intervention Phase
Beta-Thalassemia Thalassemia Major Drug: Deferiprone (DFP) and Deferoxamine (DFO) Drug: Deferiprone (DFP) Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase IV Study of the Use of Sequential DFP-DFO Versus DFP in Thalassemia Major Patients

Resource links provided by NLM:

Further study details as provided by Azienda Ospedaliera V. Cervello:

Primary Outcome Measures:
  • difference between multiple observations of the serum ferritin concentrations [ Time Frame: five-year treatment ]

Secondary Outcome Measures:
  • the difference between the T2* signal at magnetic resonance imaging (MRI) of heart and liver at T0 and T1 time (see below); survival analysis; adverse events; treatment failures; and costs. [ Time Frame: five years ]

Enrollment: 213
Study Start Date: September 2000
Study Completion Date: January 2008
Primary Completion Date: January 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Sequential treatment including DFP at 75 mg/kg, divided into three oral daily doses, for four days per week and DFO by subcutaneous infusions (8-12h) at 50 mg/kg/day for the remaining three days per week
Drug: Deferiprone (DFP) and Deferoxamine (DFO)
Sequential treatment including DFP at 75 mg/kg for four days per week and DFO by subcutaneous infusions (8-12h) at 50mg/kg/day for the remaining three days per week
Other Names:
  • DFP (Apotex, Canada)
  • DFO (Biofutura Pharma S.p.A.,Italy)
Active Comparator: 2
Deferiprone alone at 75 mg/kg divided into three oral daily doses
Drug: Deferiprone (DFP)
DFP alone at 75 mg/kg divided into three oral daily doses
Other Name: DFP (Apotex, Canada)

Detailed Description:
The trial was designed as a multicentre randomised open-label trial with blinded data management and data analyses, to assess whether either treatment was superior to the other. The trial was performed on behalf of the Italian Society for the study of Thalassemia and Haemoglobinopathies (SoSTE). The investigators initiated, carried out, and controlled the trial, which was conducted without influence of the non-commercial sponsor.16

Ages Eligible for Study:   13 Years to 60 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Thalassemia major patients with serum ferritin concentration between 800 to 3,000 ng/ml and were over 13 years of age

Exclusion Criteria:

  • Known intolerance to one of the trial treatments
  • Platelet count < 100,000/mm3 or or leukocyte count < 3,000/mm3
  • Severe liver damage indicated by ascites
  • Heart failure
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00733811

Ao V. Cervello
Palermo, Italy
Sponsors and Collaborators
Azienda Ospedaliera V. Cervello
Study Chair: AURELIO MAGGIO, M.D. Azienda Ospedaliera V. Cervello
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Aurelio Maggio, AO V Cervello Identifier: NCT00733811     History of Changes
Other Study ID Numbers: AOVCervello
Study First Received: August 11, 2008
Last Updated: August 12, 2008

Keywords provided by Azienda Ospedaliera V. Cervello:
thalassemia major
chelation treatment
secondary hemochromatosis

Additional relevant MeSH terms:
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn
Iron Chelating Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action
Siderophores processed this record on September 19, 2017